banner
PDGFR inhibitor CP-868596, Purity ≥98%
Inquiry

Cat. No.: X24-06-ZQ120

PDGFR inhibitor CP-868596, Purity ≥98%

Inquiry

Synonym: 670220-88-9; PDGFR inhibitor; CP868596; CP 868596

  • MDL: MFCD21609260
  • CAS Number: 670220-88-9
  • Compound CID: 10366136
img
Product Size
5 mg; 10 mg; 50 mg; 100 mg
Price
Datasheet
Datasheet
MSDS
MSDS
Properties
Description
CP-868596, soluble in warmed DMSO and ethanol and insoluble in water, blocks the activity of platelet-derived growth factor receptors (PDGFR), which play a crucial role in cell growth, angiogenesis, and tissue. It targets FLT3, PDGFRα (CHO cells), and PDGFRβ (CHO cells).
Molecular Weight
443.5
Molecular Formula
C26H29N5O2
Targets
FLT3: 0.74 nM (Kd); PDGFRα (CHO cells): 2.1 nM (Kd); PDGFRβ (CHO cells): 3.2 nM (Kd)
Form
Lyophilized powder
Purity
≥98%
Solubility
Warmed DMSO: 84 mg/mL (189.38 mM); Water: Insoluble; Ethanol: 7 mg/mL (15.78 mM)
Identity
Confirmed by NMR/HPLC/MS.
Applications
CP-868596 targets PDGFR, enabling investigations into its potential in disrupting cancer growth pathways.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links
(CD BioGlyco)
Lipidomics Analysis Services
(CD BioGlyco)
Glycolipid Profiling
(CD BioGlyco)
HTS of Glycan Derivatives
PRODUCTS
Featured Products
Nucleic Acid Drug Delivery Products
GalNAc-L96 intermediate, T1 (Cat#: X24-11-YM010) GalNAc-L96 intermediate, T2 (Cat#: X24-11-YM011) GalNAc-L96 intermediate, T3 (Cat#: X24-11-YM012) GalNAc-L96 intermediate, T4-Amine (Cat#: X24-11-YM014) Tri-GalNAc(OAc)3 Cbz (Cat#: X24-11-YM015) Tri-GalNAc(OAc)3 (Cat#: X24-11-YM016) Tri-GalNAc(OAc)3 TFA (Cat#: X24-11-YM017) GalNAc-L96-OH (Cat#: X24-11-YM018) GalNAc-L96-TEA (Cat#: X24-11-YM019)
Hots Products
N-Glycan
Neu5Gcα(2-6)N-Glycan (Cat#: X23-03-YW036) A2G2 N-Glycan (Cat#: X23-03-YW037) A2G2S2 N-Glycan (Cat#: X23-03-YW038) A2 N-Glycan (Cat#: X23-03-YW039) A2[6]G1 N-Glycan (Cat#: X23-03-YW040) M3 N-Glycan (Cat#: X23-03-YW041) A2[3]G2S1 N-Glycan (Cat#: X23-03-YW042)
O-Glycan
Core 2 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW178) Core 2 O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW179) Core 3 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW180) Core 3 O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW181) Core 4 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW182) T antigen O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW192) T antigen O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW193) Tn antigen O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW194)
Blood Group and Lewis Antigen
Blood group A trisaccharide (Cat#: XCO0060Q) Blood group B trisaccharide (Cat#: XCO0068Q) Blood group H disaccharide (Cat#: XCO0074Q) Lewis A trisaccharide (Cat#: XCO0079Q) 3'-Sulfated lewis A (Cat#: XCO0080Q) Lewis B tetrasaccharide (Cat#: XCO0083Q) Lewis X trisaccharide (Cat#: XCO0085Q) Lewis Y tetrasaccharide (Cat#: XCO0088Q)
Human Milk Oligosaccharides (HMOs)
Lacto-N-biose (Cat#: XCO0089Q) 2'-Fucosyllactose (Cat#: XCO0091Q) 3-Fucosyllactose (Cat#: XCO0092Q) Lactodifucotetraose (Cat#: XCO0093Q) Lacto-N-triose I (Cat#: XCO0094Q) 3'-Sialyllactose sodium salt (Cat#: XCO0096Q) 6'-Sialyllactose sodium salt (Cat#: XCO0098Q) 3'-Sialyl-3-fucosyllactose (Cat#: XCO0100Q)
Glycosaminoglycans
Heparin amine, MW 27 kDa (Cat#: X22-09-ZQ478) FITC-heparin, MW 27 kDa (Cat#: X22-09-ZQ480) TRITC-heparin, MW 27 kDa (Cat#: X22-09-ZQ481) Biotin-heparin-FITC, MW 18 kDa (Cat#: X22-09-ZQ482) Chondroitin sulfate (dp4) (Cat#: X22-11-ZQ598) Dermatan sulfate (dp12) (Cat#: X22-11-ZQ611) Heparin disaccharide I-A (Cat#: X22-11-ZQ662) Chondroitine sulfate (Cat#: X23-04-XQ1118)
Carbohydrate Conjugates
GalNAcβ(1-4)GlcNAcβ-Sp3-Biotin (Cat#: X22-12-ZQ005) GalNAcβ(1-4)GlcNAcβ-Sp3-PAA-Biotin (Cat#: X22-12-ZQ006) GalNAcβ(1-4)GlcNAcβ-Sp3-PAA-FITC (Cat#: X22-12-ZQ007) GalNAcβ(1-4)GlcNAcβ-Sp3-PAA (Cat#: X22-12-ZQ008) Glcβ(1-4)GalNAcα-Sp3-Biotin (Cat#: X22-12-ZQ037) Glcβ(1-4)GalNAcα-Sp3-PAA-Biotin (Cat#: X22-12-ZQ038) Glcβ(1-4)GalNAcα-Sp3-PAA-FITC (Cat#: X22-12-ZQ039) Glcβ(1-4)GalNAcα-Sp3-PAA (Cat#: X22-12-ZQ040)
Glycolipids
GlcCer (d18:1/8:0) (Cat#: X23-11-ZQ101) GalCer (d18:1/16:0) (Cat#: X23-11-ZQ112) LacCer (d18:1/8:0) (Cat#: X23-11-ZQ118) Lc3Cer (d18:1/8:0) (Cat#: X23-11-ZQ131) Lc4Cer (d18:1/12:0) (Cat#: X23-11-ZQ146) Sialyl-Lc4Cer (d18:1/18:0) (Cat#: X23-11-ZQ162) Lewis a Cer (d18:1/16:0) (Cat#: X23-11-ZQ175) nLc4Cer (d18:1/18:0) (Cat#: X23-11-ZQ190)
Cyclodextrin
Methyl-γ-cyclodextrin (DS 12) (Cat#: X23-11-YM119) Carboxymethyl-ɑ-cyclodextrin sodium salt (Cat#: X23-11-B003) Carboxymethyl-γ-cyclodextrin sodium salt (Cat#: X23-11-B004) Succinyl-ɑ-cyclodextrin (Cat#: X23-11-B005) Succinyl-γ-cyclodextrin (Cat#: X23-11-B006) ɑ-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B007) β-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B008) γ-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B009)
Dextran
Lysine-dextran, MW 4 kDa (Cat#: X22-09-ZQ273) Phenyl-dextran, MW 150 kDa (Cat#: X22-09-ZQ279) FITC-Q-dextran, MW 10 kDa (Cat#: X22-09-ZQ280) FITC-lysine-dextran, MW 10 kDa (Cat#: X22-09-ZQ283) TRITC-lysine-dextran, MW 10 kDa (Cat#: X22-09-ZQ287) FITC-dextran sulfate, MW 10 kDa (Cat#: X22-09-ZQ291) Dextran amine, MW 20 kDa (Cat#: X22-09-ZQ377) TRITC-dextran, MW 40 kDa (Cat#: X22-09-ZQ383) Biotin-dextran-FITC, MW 20 kDa (Cat#: X22-09-ZQ389)
Online Inquiry

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Important Links

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0